The Initiative Scope

Our initiative originates from a firm belief in the importance of scientific research on psychedelic substances and in their benefits for therapeutic purposes. Below you will find various resources that support our cause.

Psychedelic-Assisted Therapy (PAT)

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
Psilocybin-assisted psychotherapy in patients with major depressive and bipolar disorder and suicidality and significant comorbidity showed an adequate safety and tolerability profile. Importantly, repeated doses were associated with greater reductions in depression severity.

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial
In this trial patients who assumed psilocybin in combination with psychotherapy had a robust decreases in the percentage of heavy drinking days compared with those produced by active placebo and psychotherapy.

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
In this registered trial MDMA- assisted therapy reduced post PTSD symptoms and functional impairment in a population with moderate to severe PTSD and was generally well tolerated.

Scientific Studies on Psychedelics

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events.

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
Psilocybin has the potential to ameliorate intersecting pathophysiological processes relevant for both major depression and neurodegenerative diseases.

Default Mode Network Modulation by Psychedelics: A Systematic Review
What’s interesting about psychedelics and the DMN is that they induce an acute disruption in resting state connectivity within the DMN and increased functional connectivity between canonical resting-state networks, thus “redefining” DMN brain connectivity.

What are Psychedelic Substances?

Not all substances known as “drugs” are psychedelic and not all psychedelic substances are necessarily beneficial for therapeutic use. Below you will find a non-exhaustive list of the main substances that our initiative focuses on.


Psilocybin is known for its ability to create deeply spiritual and transformative experiences. This substance is being researched for its potential in psychedelic-assisted therapy to treat depression, anxiety, and addiction. Clinical studies have shown that psilocybin, administered in a therapeutic setting, can lead to significant and lasting improvements in mental health. The profound experiences induced by psilocybin help patients achieve deep introspection, emotional release, and a sense of connectedness, which are crucial for therapeutic progress.


LSD is often described as producing highly analytical and introspective experiences. This substance is explored in psychedelic-assisted therapy for its potential to treat anxiety, depression, PTSD, cluster headaches, and addiction. In a controlled therapeutic setting, LSD can facilitate profound therapeutic experiences, allowing patients to gain new insights and emotional healing. The mind-expanding effects of LSD enable individuals to break free from negative thought patterns and achieve greater mental clarity and well-being.


MDMA is being extensively studied for its use in psychedelic-assisted therapy, especially for treating post-traumatic stress disorder (PTSD). Research has shown that MDMA, when used in a controlled therapeutic setting, helps patients confront and process traumatic memories with greater emotional resilience and openness. This therapeutic approach has demonstrated significant improvements in symptoms and overall mental health, providing hope for those who have not responded to traditional treatments.


Ketamine-assisted psychotherapy (psychedelic-assisted therapy involving the use of ketamine) is utilized to treat treatment-resistant depression, anxiety, and other mental health conditions including substance use disorders. Administered via intravenous infusion or nasal spray in a controlled setting, ketamine-assisted psychotherapy allows patients to experience rapid relief from depressive symptoms, often within hours. The dissociative effects of ketamine facilitate an altered state of consciousness, enabling patients to explore their thoughts and emotions from a new perspective, leading to lasting therapeutic benefits.


DMT is unique for its ability to induce profound, immersive visions and a sense of encountering other dimensions. DMT is being studied for its use in psychedelic-assisted therapy, particularly for treating depression and anxiety. The brief but intense experiences induced by DMT can lead to significant psychological insights and emotional breakthroughs. In a therapeutic context, DMT helps patients access deep layers of the subconscious, promoting healing and personal growth.

Psychedelic’s Safety

Assessing the safe use of psychedelics for treating mental health disorders is essential. Despite the acute effects of substances such as psilocybin, ayahuasca (containing the active component DMT), LSD, and MDMA, studies on these substances have shown them to be well-tolerated in healthy individuals, psychiatric patients, and those with life-threatening illnesses such as terminal cancer patients.

Scientific studies so far have shown that the most reported adverse event associated with psychedelics was headaches. Other common adverse effects included nausea, vomiting, dizziness, fatigue, insomnia, nystagmus, euphoria, muscle tension, transient increases in blood pressure and heart rate, transient anxiety, and delusions. Most side effects typically occur within hours of intake, and there appears to be a potential dose-response relationship for side effects.

History of Psychedelic Plant Use in Europe

The discipline of Ethnobotany studies “plants used by primitive societies in various parts of the World” (R.E. Schultes, “the father of Ethnobotany; in Kochhar, 2016). In particular, its focus is on entheogens (from Ancient Greek éntheos genésthai, which means “which brings to the manifestation of the god(s) within”. Several classic ethnobotany studies investigate the use of fungi, cacti and plants found in Central and South America, and have greatly contributed to the understanding of shamanic rituals and the techniques used to bring the “god” or the “soul” to manifest. While the use of entheogens in North, Central and South America is deeply documented and studied, lesser is known about the European Continent.

We know that the Ancient Greeks used Cannabis and what today we would call opium for medical purposes, but very little is known about the compounds used in ancient Greek rituals. Wasson et al. (1978), reporting about the “Eleusinian Mysteries” proposed that not a single ingredient, rather a psychoactive compounds mix, was the key to the intoxifying concoction, whose composition we’re not sure about (it was probably a mix of Cannabis, P. Somniferum resin, or “opium”, and some sort of enzyme inhibitor like Harmaline exctracted from Peganum Harmala). Read more about the history of psychedelic use.


Here are some books that we personally recommend, both for newbies on the subject of psychedelics as well as for more in-depth information on therapy, brain research and history of medicinal plant use throughout the human history.

Want to dive in deeper?

LSD, my problem child
Albert Hoffmann

The Cosmic Serpent
Jeremy Narby


There are many documentaries talking about psychedelic substances and their effects on our mind. We have made a selection for you, focusing specifically on their therapeutic effects.